Novo Nordisk A/S
Novo Nordisk A/S (NONOF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Novo Nordisk A/S (NONOF), covering cash flow, earnings, and balance sheets.
Novo Nordisk A/S (NONOF) Income Statement & Financial Overview
Analyze Novo Nordisk A/S’s NONOF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $78.09B | $85.68B | $71.31B | $68.06B |
| Cost of Revenue | $12.89B | $13.02B | $11.31B | $10.27B |
| Gross Profit | $65.20B | $72.66B | $60.003B | $57.79B |
| Gross Profit Ratio | $0.83 | $0.85 | $0.84 | $0.85 |
| R&D Expenses | $10.31B | $13.80B | $9.49B | $16.17B |
| SG&A Expenses | $16.11B | $20.28B | $16.59B | $16.09B |
| Operating Expenses | $26.41B | $35.92B | $26.18B | $31.85B |
| Total Costs & Expenses | $39.30B | $48.95B | $37.49B | $42.13B |
| Interest Income | $3.42B | -$2.65B | $1.38B | $960.00M |
| Interest Expense | $5.18B | -$2.53B | $821.00M | $1.56B |
| Depreciation & Amortization | $3.83B | -$5.36B | $2.15B | $8.85B |
| EBITDA | $46.05B | $27.38B | $37.35B | $35.74B |
| EBITDA Ratio | $0.59 | $0.32 | $0.52 | $0.53 |
| Operating Income | $38.79B | $36.74B | $33.82B | $25.93B |
| Operating Income Ratio | $0.50 | $0.43 | $0.47 | $0.38 |
| Other Income/Expenses (Net) | -$1.76B | -$1.18B | $562.00M | -$602.00M |
| Income Before Tax | $37.03B | $35.56B | $34.38B | $25.33B |
| Income Before Tax Ratio | $0.47 | $0.41 | $0.48 | $0.37 |
| Income Tax Expense | $8.00B | $7.33B | $7.08B | $5.28B |
| Net Income | $29.03B | $28.23B | $27.30B | $20.05B |
| Net Income Ratio | $0.37 | $0.33 | $0.38 | $0.29 |
| EPS | $6.54 | $6.34 | $6.13 | $4.50 |
| Diluted EPS | $6.53 | $6.34 | $6.12 | $4.49 |
| Weighted Avg Shares Outstanding | $4.44B | $4.45B | $4.45B | $4.46B |
| Weighted Avg Shares Outstanding (Diluted) | $4.45B | $4.46B | $4.46B | $4.47B |
Financial performance has remained strong, with revenue growing from $68.06B in Q2 2024 to $78.09B in Q1 2025. Gross profit continued to perform well, with margins at 83% in the latest quarter. Operating income reached $38.79B in Q1 2025, holding a steady 50% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $46.05B. Net income rose to $29.03B, keeping EPS at $6.54. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan